ClinicalTrials.gg
CompletedNCT06619847Updated May 28, 2026

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

A Phase 2 interventional study of VX-993 and HB/APAP in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated — none open to participants now, none under way, none of them phase 3. Acute Pain · Vertex Pharmaceuticals Incorporated.

Enrollment
3rd of 10
367 · median 262
Started
2024
the only one that year
Phase 2
5 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated, this one is the 3rd largest by enrollment, is the only one that started in 2024, is one of 5 in phase 2, and was the 8th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

None of the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated is open now. The open studies under Acute Pain, anywhere →

Where they have run

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.

03

Conditions studied

  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Before Surgery:

  • Participant scheduled to undergo a primary unilateral bunionectomy with distal first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under regional anesthesia (Mayo block)

After Surgery:

  • Participant is lucid and able to follow commands
  • All analgesic guidelines were followed during and after the bunionectomy

Key Exclusion Criteria:

Before Surgery:

  • Prior history of bunionectomy or other foot surgery on the index foot
  • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) within the last 2 years
  • A known or clinically suspected active infection with or or C viruses

After Surgery:

  • Participant had a Type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair, or had medical complications during the bunionectomy

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
367 participants (actual)

Study arms

  • Experimental
    VX-993

    Participants will be randomized to receive different dose levels of VX-993.

    Drug: VX-993 · Drug: Placebo (matched to HB/APAP)

  • Active comparator
    Hydrocodone bitartrate/acetaminophen (HB/APAP)

    Participants will be randomized to receive HB/APAP.

    Drug: HB/APAP · Drug: Placebo (matched to VX-993)

  • Placebo comparator
    Placebo

    Participants will be randomized to receive placebo matched to VX-993 and HB/APAP

    Drug: Placebo (matched to VX-993) · Drug: Placebo (matched to HB/APAP)

Interventions

  • DrugVX-993

    Tablets for oral administration.

  • DrugHB/APAP

    Drug pages: Hydrocodone · Acetaminophen

    Capsules for oral administration.

  • DrugPlacebo (matched to VX-993)

    Placebo matched to VX-993 for oral administration.

  • DrugPlacebo (matched to HB/APAP)

    Placebo matched to HB/APAP for oral administration.

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of Pain Intensity Difference (SPID) as Recorded on the Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48)

    Time frame: From 0 to 48 Hours After the First Dose of Study Drug

Secondary outcomes

  1. Proportion of Participants With Greater Than or Equal To (>=) 30 Percent (%) Reduction in NPRS at 48 Hours

    Time frame: At 48 Hours After the First Dose of Study Drug

  2. Proportion of Participants With >=50% Reduction in NPRS at 48 Hours

    Time frame: At 48 Hours After the First Dose of Study Drug

  3. Proportion of Participants With >=70% Reduction in NPRS at 48 Hours

    Time frame: At 48 Hours After the First Dose of Study Drug

  4. Maximum Observed Plasma Concentration (Cmax) of VX-993 and its Metabolite

    Time frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug

  5. Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-993 and its Metabolite

    Time frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax) of VX-993 and its Metabolite

    Time frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug

  7. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 19

07

Study locations

14 sites
  • Shoals Medical Trials Inc.
    Sheffield, Alabama 35660, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Trovare Clinical Research
    Bakersfield, California 93301, United States
  • New Hope Research Development | Tarzana, CA
    Tarzana, California 91356, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33172, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • HD Research LLC | First Surgical Hospital
    Bellaire, Texas 77401, United States
  • HD Research LLC | Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • Memorial Hermann Village
    Houston, Texas 77043, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2025, 6 months.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Oct 1, 2024
StartActual
Oct 29, 2024
Primary completionActual
May 27, 2025
CompletionActual
May 27, 2025
Results delay requested
May 26, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06619847
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 29, 2024
Primary completion
May 27, 2025
Completion
May 27, 2025
Last update
May 28, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VX-993

Start the discussion